Travelzoo (TZOO) Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Travelzoo in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TZOO shares.
View TZOO analyst ratings or view top-rated stocks.

2 Wall Street analysts have issued 12 month price targets for Travelzoo's shares. Their TZOO share price forecasts range from $16.00 to $18.00. On average, they predict the company's stock price to reach $17.00 in the next twelve months. This suggests a possible upside of 79.9% from the stock's current price.
View analysts price targets for TZOO or view top-rated stocks among Wall Street analysts.

Travelzoo's stock was trading at $4.45 at the beginning of 2023. Since then, TZOO shares have increased by 112.4% and is now trading at $9.45.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 26th 2023.
View our TZOO earnings forecast.

Travelzoo (NASDAQ:TZOO) issued its quarterly earnings data on Wednesday, March, 22nd. The information services provider reported $0.20 earnings per share for the quarter, beating the consensus estimate of $0.12 by $0.08. The information services provider had revenue of $18.61 million for the quarter, compared to analysts' expectations of $18.45 million. Travelzoo had a net margin of 10.78% and a trailing twelve-month return on equity of 220.30%.

59 employees have rated Travelzoo Chief Executive Officer Holger Bartel on Glassdoor.com. Holger Bartel has an approval rating of 44% among the company's employees. This puts Holger Bartel in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Travelzoo investors own include Onconova Therapeutics (ONTX), Allena Pharmaceuticals (ALNA), T2 Biosystems (TTOO), Arbutus Biopharma (ABUS), Amarin (AMRN), Ford Motor (F), Las Vegas Sands (LVS), OPKO Health (OPK), Sorrento Therapeutics (SRNE) and AbbVie (ABBV).

Travelzoo trades on the NASDAQ under the ticker symbol "TZOO."

Travelzoo's stock is owned by a variety of retail and institutional investors. Top institutional investors include Forager Capital Management LLC (3.23%), Renaissance Technologies LLC (2.50%), Acadian Asset Management LLC (2.28%), Dimensional Fund Advisors LP (1.82%), BlackRock Inc. (0.85%) and Aristides Capital LLC (0.16%). Insiders that own company stock include Azzurro Capital Inc, Holger Bartel, Lisa Su and Ralph Bartel.
View institutional ownership trends.

Shares of TZOO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TZOO stock can currently be purchased for approximately $9.45.

Travelzoo (NASDAQ:TZOO) has a market capitalization of $147.04 million and generates $70.60 million in revenue each year. The information services provider earns $6.63 million in net income (profit) each year or $0.57 on an earnings per share basis.

The company employs 214 workers across the globe.

Travelzoo's mailing address is 590 Madison Avenue 35th Floor, New York NY, 10022. The official website for the company is www.travelzoo.com. The information services provider can be reached via phone at (212) 484-4900, via email at ir@travelzoo.com, or via fax at 212-521-4230.